Annotation Detail
Information
- Associated Genes
- HRAS
- Associated Variants
-
HRAS p.Gly13Asp (p.G13D)
(
ENST00000311189.8,
ENST00000397594.7,
ENST00000397596.6,
ENST00000417302.7,
ENST00000451590.5 )
HRAS p.Gly13Asp (p.G13D) ( ENST00000311189.8, ENST00000397594.7, ENST00000397596.6, ENST00000417302.7, ENST00000451590.5 ) - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- In an in vitro study, Colo-320, SW48, and CaCO2 cell lines expressing HRAS G13D mutation were associated with resistance to cetuximab treatment, as compared to Colo-320, SW48, and CaCO2 cells expressing wild-type HRAS.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/3852
- Gene URL
- https://civic.genome.wustl.edu/links/genes/2747
- Variant URL
- https://civic.genome.wustl.edu/links/variants/274
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Cetuximab
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 26561417
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cetuximab | Resitance or Non-Reponse | true |